Journal of Advanced Zoology

ISSN: 0253-7214

*Volume **44** Issue **S-1 Year 2023** Page **911:916***

Role of Neoadjuvant Paclitaxel Chemotherapy in Carcinoma Breast: A Prospective Study

S. J. Bhosale[1*], Nitin R. Nanagre[2], R.G. Naniwadekar[3]

[1,2,3]Department of General Surgery Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

Email: docnitiraj@gmail.com[2], drrgnaniwadekar@gmail.com[3]

**Corresponding author's E-mail: dr.sureshbhosale@gmail.com*

Article History

Received: 06 June 2023
Revised: 05 Sept 2023
Accepted: 13 Oct 2023

Abstract

***Objective**: The purpose of this prospective study was to assess the value of neoadjuvant chemotherapy with paclitaxel in the treatment of breast cancer. **Methods**: There were 88 diagnosed breast cancer patients altogether, 44 in each of the two groups (paclitaxel group and control group). To verify eligibility, thorough clinical, radiological, and laboratory evaluations were made. The reduction of tumor size, pathological reactions, and safety profiles were evaluated. To compare results between groups, statistical tests were used during data processing. **Results**: At 12 and 24 weeks, the paclitaxel group showed significantly smaller tumor sizes than the control group. In the paclitaxel group, complete pathological responses were more common, indicating efficient tumor regression. The side effects of paclitaxel therapy were generally well-tolerated and controllable. **Conclusion**: In conclusion, patients with breast cancer showed encouraging improvements in histological responses and tumor size after neoadjuvant paclitaxel treatment. These results suggest the potential advantages of using paclitaxel in neoadjuvant therapy protocols, perhaps making breast-conserving surgery more feasible. In order to provide more individualized treatments, future research should investigate long-term outcomes and biomarkers indicative of paclitaxel sensitivity.*

Keywords: *Breast Cancer, Neoadjuvant Chemotherapy, Paclitaxel, Prospective Study, Treatment Outcomes*

1. Introduction

A large fraction of cancer diagnoses globally and a sizable portion of cancer-related fatalities among women are due to breast cancer, which continues to be a serious global health issue [1]. Breast cancer is complicated and heterogeneous, which has prompted the development of diverse treatment approaches that attempt to achieve the best therapeutic results while minimizing side effects and maintaining patients' quality of life. Neoadjuvant chemotherapy is one such tactic that has attracted more interest recently.

Neoadjuvant chemotherapy is when chemotherapy is given before to initial surgical intervention with the main objective of lowering tumor burden and maybe improving the viability of breast-conserving surgery [2]. This method has a number of benefits, including the ability to analyze the tumor's response to therapy, modify therapeutic regimens based on the responses of specific patients, and begin systemic therapy early in cases with aggressive tumor features [3]. Because of its demonstrated effectiveness in treating several cancer types, including breast cancer, paclitaxel, a taxane derivative, has attracted particular attention among the different chemotherapeutic drugs used in neoadjuvant regimens [4].

The use of paclitaxel in the neoadjuvant context for the treatment of breast cancer is still a developing field of study and therapeutic use. The goal of this prospective study is to thoroughly examine and advance our knowledge of the function of neoadjuvant paclitaxel chemotherapy in the context of breast cancer.

Arguments in Support of Neoadjuvant Chemotherapy for Breast Cancer Amazing clinical and molecular heterogeneity is present in breast cancer, with several subtypes distinguished by differences in receptor status, genetic changes, and clinical behavior [5]. This variety makes it difficult to choose the best treatment plans, emphasizing the value of personalised treatments. Neoadjuvant chemotherapy enables early tumor response to treatment assessment, allowing clinicians to customize follow-up therapies based on the behavior of the tumor.

Neoadjuvant chemotherapy may assist breast-conserving surgery in addition to its potential to shrink tumors, which is an important factor for many patients who want to preserve their breasts without sacrificing their oncologic results [6]. Decisions about postoperative adjuvant therapy are influenced and useful prognostic information is provided by the capacity to assess pathological reactions following treatment [7].

Treatment of Breast Cancer with Paclitaxel: A microtubule-stabilizing drug called paclitaxel has proven to be remarkably effective in treating a number of cancers, including breast cancer. Paclitaxel prevents cancer cell growth and impairs cell division by interfering with microtubule dynamics [8]. Additionally, paclitaxel has shown synergistic effects when combined with other chemotherapeutic drugs and targeted therapies, making it a viable addition to combination regimens [9].

Paclitaxel-based chemotherapy has demonstrated increases in disease-free survival and overall survival for patients with breast cancer in the adjuvant situation [10]. However, research is still being done to determine its exact function and advantages in the neoadjuvant setting. Through a thorough analysis of the influence of neoadjuvant paclitaxel chemotherapy on breast cancer treatment outcomes, this study aims to add to the body of current evidence.

Research Goals: This prospective study's main goal is to evaluate the function of neoadjuvant paclitaxel chemotherapy in the treatment of breast cancer.

1. First, we want to assess how neoadjuvant paclitaxel treatment affects tumor size reduction.
2. Compare the rates of pathological response in patients receiving neoadjuvant paclitaxel to those getting conventional care.
3. Examine the overall effectiveness of the treatment, taking into account both surgical outcomes and patient feedback.
4. Examine the neoadjuvant paclitaxel chemotherapy's safety and tolerability in patients with breast cancer.

By focusing on these goals, we hope to give doctors evidence-based understanding of the possible benefits and restrictions of paclitaxel inclusion in neoadjuvant therapy protocols for breast cancer. Additionally, in line with the larger objective of enhancing patient care and long-term results for those dealing with this tough disease, our study aims to add to the ongoing conversation on tailored treatment approaches for breast cancer.

2. Materials And Methods

Study Design: This prospective study was conducted at the Department of Surgery, in collaboration with tertiary care centers, from December 2020 to July 2022. The study design adheres to ethical guidelines and has received approval from the institutional review board (IRB) and the ethics committee. Informed consent will be obtained from all study participants before enrollment.

Study Participants: A total of 88 patients with diagnosed breast cancer were included in this study. Patients were divided into two groups: the paclitaxel group and the control group, with each group comprising 44 patients.

Inclusion Criteria:

1. Confirmed diagnosis of breast carcinoma based on histopathology.
2. Voluntary participation in the study.
3. Ability to attend follow-up assessments.

4. Adequate organ function as determined by laboratory tests.

Exclusion Criteria:

1. Prior history of chemotherapy or radiation therapy for breast cancer.
2. Contraindications to paclitaxel therapy, including known hypersensitivity reactions.
3. Presence of other malignancies or significant comorbidities that may impact study outcomes.

Randomization: Patients were randomized into either the paclitaxel group or the control group using computer-generated randomization codes. Allocation concealment were ensured to minimize bias in group assignment.

Intervention (Paclitaxel Group): Patients in the paclitaxel group received neoadjuvant paclitaxel chemotherapy. Paclitaxel was administered intravenously. Dose adjustments were made as necessary based on individual patient tolerance and treatment response.

Control Group: Patients in the control group received standard treatment according to current clinical guidelines, that included various chemotherapy regimens, targeted therapies, and hormonal therapy as indicated based on the specific breast cancer subtype and stage.

Data Collection:

1. **Baseline Assessment:** Before the initiation of treatment, all patients underwent a comprehensive assessment, including clinical evaluation, imaging (e.g., mammography, ultrasound, MRI), and laboratory tests (complete blood count, liver function tests, renal function tests, tumor markers, HER2 status, hormone receptor status, and genetic profiling).
2. **Treatment Monitoring:** Throughout the study, patients were closely monitored for treatment response and any adverse effects. Clinical assessments will be conducted at regular intervals, including physical examinations and laboratory evaluations as appropriate.
3. **Tumor Size Measurement:** Tumor size were measured using appropriate imaging modalities, and the results will be recorded at baseline and at specified time points during treatment.
4. **Pathological Assessment:** Surgical specimens obtained during definitive surgery (mastectomy or lumpectomy) underwent detailed pathological assessment. Pathological response rates, including complete response, partial response, stable disease, and progression, will be documented.

Statistical Analysis: Statistical analysis were performed using appropriate tests to compare the outcomes between the paclitaxel group and the control group. Descriptive statistics summarized baseline characteristics, treatment responses, and adverse events. Inferential statistics, such as chi-squared tests and t-tests, were employed to assess differences between groups.

3. Results and Discussion

Baseline Characteristics: At baseline, the paclitaxel and control groups were well-matched in terms of age, tumor stage, hormone receptor status, and HER2 status (Table 1). The mean age of participants was similar in both groups, with the majority having stage II tumors. Most patients in both groups had hormone receptor-positive tumors, and HER2 status was evenly distributed.

Tumor Size Reduction: The assessment of tumor size reduction at various time points during treatment revealed notable differences between the paclitaxel group and the control group (Table 2). At baseline, the mean tumor size in the paclitaxel group was 4.8 cm, while in the control group, it was 4.6 cm. After 12 weeks of treatment, the paclitaxel group exhibited a substantial reduction in tumor size, with a mean size of 2.1 cm, compared to 3.3 cm in the control group. By week 24, the paclitaxel group further reduced the tumor size to a mean of 1.0 cm, while the control group showed a mean size of 2.7 cm. These findings suggest that neoadjuvant paclitaxel chemotherapy led to a more significant reduction in tumor size compared to standard treatment.

Pathological Response Rates: The assessment of pathological responses following surgery demonstrated a higher rate of complete responses in the paclitaxel group compared to the control group

(31.8% vs. 9.1%). Additionally, the paclitaxel group showed a higher rate of partial responses (59.1% vs. 54.5%). Conversely, fewer patients in the paclitaxel group had stable disease (9.1% vs. 27.3%), and none experienced disease progression, while a subset of patients in the control group did (9.1%) (Table 3). These results indicate a more favorable pathological response profile in the paclitaxel group.

Table 1: Baseline Characteristics of Study Participants

Characteristic	Paclitaxel Group (n=44)	Control Group (n=44)
Age (years)	54.2 ± 8.1	52.8 ± 7.5
Tumor Stage		
- Stage I	12 (27.3%)	14 (31.8%)
- Stage II	24 (54.5%)	20 (45.5%)
- Stage III	8 (18.2%)	10 (22.7%)
Hormone Receptor		
- Positive (%)	30 (68.2%)	32 (72.7%)
- Negative (%)	14 (31.8%)	12 (27.3%)
HER2 Status		
- Positive (%)	16 (36.4%)	18 (40.9%)
- Negative (%)	28 (63.6%)	26 (59.1%)

Table 2: Tumor Size Reduction in Response to Treatment

Time Point (weeks)	Paclitaxel Group (n=44)	Control Group (n=44)
Baseline	4.8 ± 1.2 cm	4.6 ± 1.1 cm
Week 12	2.1 ± 0.8 cm	3.3 ± 1.0 cm
Week 24	1.0 ± 0.5 cm	2.7 ± 0.9 cm

Table 3: Pathological Response Rates

Response Category	**Paclitaxel Group (%)**	**Control Group (%)**
Complete Response	14 (31.8%)	4 (9.1%)
Partial Response	26 (59.1%)	24 (54.5%)
Stable Disease	4 (9.1%)	12 (27.3%)
Progression	0 (0.0%)	4 (9.1%)

Our prospective study's results provided insight into the possible advantages and drawbacks of neoadjuvant paclitaxel chemotherapy in the treatment of breast cancer. Comprehensive analysis of tumor responses, pathology results, and therapy safety is clinically significant and may influence how we treat breast cancer.

Tumor Size Reduction and Breast-Conserving Surgery Possibility:

Reducing tumor size may increase the viability of breast-conserving surgery (BCS), which is one of the main goals of neoadjuvant chemotherapy in breast cancer. In comparison to the control group, our study showed a striking decrease in tumor size in the paclitaxel group. This reduction became noticeable after 12 weeks of treatment and got better over time. These findings are interesting in particular because they imply that neoadjuvant paclitaxel therapy may increase the likelihood of BCS, a treatment option that many patients prefer [11-13].

For breast cancer survivors, BCS has significant emotional and cosmetic ramifications in addition to addressing the oncological element of treatment. More patients being able to receive BCS can enhance their general quality of life and satisfaction with the results of their treatment. However, it is crucial to remember that complete cancer eradication with visible surgical margins should always take precedence in BCS decisions.

Pathological Response Rates: Following neoadjuvant chemotherapy, pathological responses are important prognostic indications and might direct further treatment choices. In our investigation, we

found that the paclitaxel group had a higher rate of full pathological reactions than the control group. Complete responses indicate the elimination of invasive cancer, which may produce better long-term results. This result is consistent with other studies that indicated paclitaxel-based regimens could result in higher pathological response rates [11-15].

The paclitaxel group also had a larger percentage of partial responses, which suggested significant tumor reduction. Neoadjuvant paclitaxel treatment appears to successfully manage and lower tumor burden based on the combination of complete and partial responses. The potential therapeutic benefit of paclitaxel in attaining more widespread tumor shrinkage was highlighted by the fact that the control group had a lower percentage of patients obtaining full responses and a higher rate of stable illness.

Security and Acceptability:

The safety and tolerability of any neoadjuvant therapy must be taken into account. The safety profile of neoadjuvant paclitaxel chemotherapy was a key component of the investigation in our study. A key component of our study's design involved monitoring for adverse events, such as hematological toxicity, neuropathy, and other potential side effects.

The findings showed that the trial subjects generally tolerated neoadjuvant paclitaxel therapy satisfactorily. No unexpected or severe toxicities were seen, and adverse events were appropriately treated. This result is in line with the known safety profile of paclitaxel used to treat breast cancer [12-14]. Paclitaxel's usefulness as a neoadjuvant drug is further supported by the fact that it may be administered without endangering patient safety.

Literature Comparative

It is crucial to contrast our results with the body of knowledge on neoadjuvant chemotherapy in breast cancer in order to contextualize our findings. The effectiveness of paclitaxel-based neoadjuvant regimens has been the subject of numerous research, with various degrees of success. The observed improvements in tumor size reduction and pathological response rates in the paclitaxel group highlight the potential benefits of including paclitaxel in neoadjuvant treatment protocols. Our results are consistent with studies reporting favorable tumor size reduction and higher rates of complete pathological responses associated with paclitaxel [3]. These findings are especially important for patients with larger tumors since reducing the tumors before surgery may be beneficial for them.

Future Directions and Restrictions:

Although our study offers insightful information about neoadjuvant paclitaxel treatment, it has certain drawbacks. There are certain inherent limitations that should be taken into account, including the relatively small sample size and the brief follow-up period. Our findings may be strengthened by a larger, longer-term trial that would also provide more solid data about the influence of paclitaxel on long-term outcomes, such as disease-free survival and overall survival.

Furthermore, the potential molecular or genetic factors that could affect therapy outcomes were not examined in our investigation. Future studies could focus on these areas to find biomarkers indicative of paclitaxel sensitivity, enabling more specialized therapeutic strategies.

4. Conclusion

In summary, this prospective study adds substantial evidence in favor of the use of neoadjuvant paclitaxel chemotherapy in the treatment of breast cancer. The good pathology responses, reported tumor size reductions, and controllable safety profile highlight the potential advantages of using paclitaxel in neoadjuvant therapy regimens. These results may have an impact on clinical practice by providing a robust treatment alternative that could increase the viability of breast-conserving surgery and improve patient outcomes. It is necessary to do additional research, including larger-scale and longer-term studies, to confirm and build upon these encouraging findings.

References:

1. Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Singh K B. A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma. Breast Cancer (Dove Med Press). 2020 Nov 20;12:259- 266. doi: 10.2147/BCTT.S277588. PMID: 33262647; PMCID: PMC7686913.

2. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M and Soon-Shiong P: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317- 1324, 2006.
3. Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., ... & Hudis, C. A. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33(1), 13-21..
4. Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12:625-9.
5. Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer 2010;47:8-15.
6. James R, Thriveni K, Ramaswamy G, Krishnamoorthy L, Mukherjee G, Vijayalaxmi Deshmane PP, et al. Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinoma. Indian J Clin Biochem 2008;23:345-51.
7. Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev 2009;10:773-8.
8. Alvarado-Cabrero I, Alderete-Vazquez G, Quintal- Ramirez M, Patino M, Ruiz E. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: cor- relation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. *Ann Diagn Pathol*. 2009;13(3):151–157.
9. Mishra S et al. Clinico-pathological response and operability after neoadjuvant chemotherapy in locally advanced breast carcinoma. International journal of scientific research. Volume-8, Issue-12, 2019. 57-61
10. Hortobagyi GN,et al: MD Anderson hospital ; Management of stage III primary breast cancer with primary CT/Surgery/ Radiation.1988 Dec 15;62(12):2507-16
11. Ochonma Amobi Egwuonwu, Anyanwu SN, Nwofor AM. Efficacy of neoadjuvant chemotherapy in down staging locally advanced pre- menopausal breast cancer in Eastern Nigeria: Is four courses adequate?. Journal of cancer research and therapeutics. 2013 Oct 1;9(4):638
12. Kimura M, Sano M, Fujimori M, Nakagomi H, Negishi T, Yanagita Y, Sato N. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer Res. 2008 Mar-Apr;28(2B):1239-44. PMID: 18505061.
13. Del Prete S, et al. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: a single center experience. *Oncol Lett*. 2019;18(4):3873–3879. doi: 10.3892/ol.2019.10729